Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study
Authors
Rong Huang (ORCID: https://orcid.org/0000-0002-2095-3883)
Kai Shen (ORCID: https://orcid.org/0009-0009-0439-635X)
Yu Cao (ORCID: https://orcid.org/0000-0003-1992-509X)
Feifei Sun (ORCID: https://orcid.org/0000-0002-8161-536X)
Xiaotong Hu (ORCID: https://orcid.org/0009-0004-7958-4869)
Pingping Lin (ORCID: https://orcid.org/0000-0002-0495-8553)
Lin Fang (ORCID: https://orcid.org/0000-0003-2418-3617)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study
Rong Huang, Kai Shen, Yu Cao, Feifei Sun et al.
Citations
1 citations
Journal
Expert Opinion on Investigational Drugs
Topics
Complement system in diseases
Field-Weighted Citation Impact (FWCI)
0.80
article
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study
Rong Huang, Kai Shen, Yu Cao, Feifei Sun, Xiaotong Hu, Pingping Lin, Lin Fang, Sheng Feng, Hongda Lin, Chenjing Wang, Rongxin Ban, Zhenyan Gao
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Expert Opinion on Investigational DrugsVol. 34(4)
Institutions
Qingdao University (CN), Affiliated Hospital of Qingdao University (CN), Jiangsu Hengrui Medicine (China) (CN)